Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) EBITDA (2017 - 2025)

Historic EBITDA for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to -$36.7 million.

  • Dianthus Therapeutics' EBITDA fell 5006.54% to -$36.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$126.9 million, marking a year-over-year decrease of 9103.86%. This contributed to the annual value of -$84.9 million for FY2024, which is 9588.44% down from last year.
  • According to the latest figures from Q3 2025, Dianthus Therapeutics' EBITDA is -$36.7 million, which was down 5006.54% from -$31.8 million recorded in Q2 2025.
  • Dianthus Therapeutics' EBITDA's 5-year high stood at -$7.0 million during Q1 2023, with a 5-year trough of -$36.7 million in Q3 2025.
  • For the 4-year period, Dianthus Therapeutics' EBITDA averaged around -$18.8 million, with its median value being -$14.7 million (2023).
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 380.17% in 2023, then tumbled by 17601.79% in 2024.
  • Quarter analysis of 4 years shows Dianthus Therapeutics' EBITDA stood at -$10.1 million in 2022, then dropped by 3.8% to -$10.5 million in 2023, then crashed by 176.02% to -$29.0 million in 2024, then decreased by 26.49% to -$36.7 million in 2025.
  • Its EBITDA stands at -$36.7 million for Q3 2025, versus -$31.8 million for Q2 2025 and -$29.3 million for Q1 2025.